Sindilizumab injection is referred to as Sindilizumab injection, a course of treatment usually costs 2000-3000 yuan, but the price may vary from region to region. Sindilizumab injection is currently used in China for classic Hodgkin’s lymphoma that has relapsed after second-line systemic chemotherapy, and can also be combined with other drugs for lung squamous cell carcinoma, small cell lung cancer, or unresectable liver cancer that has not received systemic therapy. Sindilizumab injection has entered a new round of price reduction, one is about 1000 yuan, a course of Sindilizumab injection usually uses two drugs, so a course of treatment needs 2000-3000 yuan, but the price may vary from region to region and from hospital to hospital, usually the price of a course of treatment using two drugs does not exceed 3000 yuan. With the price reduction of Sindilizumab injection and its inclusion in the medical insurance, the burden of treatment is further reduced and more patients are able to benefit from Sindilizumab injection. Some complications may occur with the use of Sindilizumab Injection, mainly fever, anemia, abnormal thyroid function, etc. It can also cause unique immune adverse reactions, including immune-related pneumonia, diarrhea, and colitis, and the occurrence of adverse reactions should be closely monitored during the application of Sindilizumab Injection and given prompt treatment.